TScan Therapeutics, Inc. (TCRX)
Automate Your Wheel Strategy on TCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including TCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TCRX
- Rev/Share 0.0341
- Book/Share 1.6209
- PB 0.8822
- Debt/Equity 0.4616
- CurrentRatio 8.547
- ROIC -0.4466
- MktCap 80924595.0
- FreeCF/Share -0.9546
- PFCF -0.6537
- PE -1.4104
- Debt/Assets 0.2917
- DivYield 0
- ROE -0.5622
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.
Read More
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience
Read More
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025.
Read More
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Negative
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago.
Read More
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time.
Read More
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.
Read More
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
Read More
About TScan Therapeutics, Inc. (TCRX)
- IPO Date 2021-07-16
- Website https://www.tscan.com
- Industry Biotechnology
- CEO Dr. Gavin MacBeath Ph.D.
- Employees 200